Sinan Umit Yasar, Yilmaz Mehmet Birhan, Temizhan Ahmet, Yuksel Uygar Cagdas, Gungor Baris, Kemaloglu Oz Tugba, Kus Mesut, Ozdogan Oner, Kayikcioglu Meral, Tokgozoglu Lale
Department of Cardiology, Istanbul University-Cerrahpasa Institute of Cardiology, Haseki Sultan Haseki Cd. No: 32, 34096, Fatih, Istanbul, Turkey.
Department of Cardiology, Dokuz Eylul University Faculty of Medicine, Izmir, Turkey.
Sci Rep. 2024 Dec 28;14(1):31307. doi: 10.1038/s41598-024-82780-2.
This study evaluated the management of dyslipidemia in Turkey with the goal of understanding current diagnosis and treatment patterns, as well as identifying unmet needs in achieving effective low-density lipoprotein cholesterol (LDL-C) targets. Using a Delphi panel consisting of nine expert cardiologists, the study reveals key gaps in dyslipidemia management, particularly in the underutilization of combination therapies, such as statins and PCSK9 inhibitors, which are crucial for achieving LDL-C targets in high-risk patients. The findings indicate that while many patients with very high cardiovascular risk are diagnosed, a significant proportion do not receive optimal treatment to reach LDL-C levels recommended by European guidelines. Addressing these gaps could lead to more effective management of dyslipidemia and reduce the burden of cardiovascular disease in Turkey. The study's insights provide critical recommendations for clinicians and policymakers to improve clinical practice and health outcomes through more aggressive lipid-lowering strategies.
本研究评估了土耳其血脂异常的管理情况，目的是了解当前的诊断和治疗模式，并确定在实现有效的低密度脂蛋白胆固醇（LDL-C）目标方面未满足的需求。该研究通过一个由九位心脏病专家组成的德尔菲小组，揭示了血脂异常管理中的关键差距，特别是在联合治疗（如他汀类药物和PCSK9抑制剂）的使用不足方面，而联合治疗对于高危患者实现LDL-C目标至关重要。研究结果表明，虽然许多心血管风险极高的患者得到了诊断，但仍有很大一部分患者未接受最佳治疗以达到欧洲指南推荐的LDL-C水平。填补这些差距可能会使土耳其的血脂异常管理更加有效，并减轻心血管疾病负担。该研究的见解为临床医生和政策制定者提供了关键建议，以便通过更积极的降脂策略改善临床实践和健康结果。
